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Introduction {#sec1}
============

Pancreatic ductal adenocarcinoma (PDA) is a leading cause of cancer death ([@bib37]). It is poorly responsive to available chemotherapies and unresponsive to checkpoint-targeted immunotherapies ([@bib3], [@bib35]), and it predisposes patients to the lethal wasting syndrome, cachexia ([@bib2]). Resistance to chemotherapy and immune evasion are topics of active research in PDA ([@bib12], [@bib29]), but how PDA tumors alter host metabolism in cachexia and whether this affects the host's immune interaction with the tumor are less studied questions.

Cachexia, which is clinically defined by weight loss, represents a spectrum of disease. It initially arises as pre-cachexia, progresses to cachexia, and then progresses to refractory cachexia, a process that is driven by negative energy balance and abnormal metabolism ([@bib9]). The pathogenesis and progression of cachexia have been attributed in part to systemic elevations of pro-inflammatory cytokines ([@bib10]), but anti-cytokine therapies alone have not demonstrated clinical benefit. Cachexia-enhancing alterations such as increased catabolic signaling and increased uncoupling protein expression have also been described at the level of muscle and fat tissues, respectively ([@bib21], [@bib31], [@bib47]). It is not known, however, whether the normal host response to caloric deficiency, a central component of the syndrome ([@bib9]), is itself impaired in cachexia. Such an impairment might explain why macronutrient supplementation has failed to reverse cachexia in clinical trials ([@bib41]).

Altered macronutrient utilization must also be considered in the context of tumor biology and therapeutic resistance. Previous studies have highlighted the capacity of cancer cells to respond to alterations of the host metabolism ([@bib17], [@bib30]), but the stromal constituents of the tumor may also sense such alterations. One possibility, considering the sensitivity of intratumoral T cells to their local metabolic environment ([@bib6], [@bib15]), as well as the marked effects of poor nutritional status on systemic immunity in other contexts ([@bib20]), is a suppressive effect of cachexia on the T cell-mediated anti-tumor immune reaction. Such an effect could contribute to the failure of patients with PDA to respond to the current generation of T cell checkpoint targeted immunotherapies.

In the present study, we have examined the interactions between cancer, systemic metabolism, and tumor immunology in mice using two cancer types that have been documented to predispose to cachexia, the transplanted C26 model of colorectal cancer ([@bib40]) and the genetically engineered, autochthonous LSL-Kras^G12D/+^; LSL-Trp53^R172H/+^; Pdx-1-Cre/+ (KPC) model of PDA ([@bib14], [@bib33]).

Results {#sec2}
=======

Reprogrammed Hepatic Metabolism Is Evident in Pre-cachectic and Cachectic Mice {#sec2.1}
------------------------------------------------------------------------------

C26 and PDA tumors cause cachexia, as defined by loss of body weight ([Figures 1](#fig1){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B, available online), depletion of fat and muscle mass ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1F), and elevated markers of muscle catabolism ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1G). In both model systems, we observed that cachexia was associated with decreased food intake ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}C). The cachexia-associated reduction in food intake was more pronounced in PDA-bearing relative to C26-bearing mice despite similar rates of weight loss, possibly reflecting differences in tumor size, tumor metabolic activity, and/or murine activity levels. Given the relevance of reduced food intake to cachexia ([@bib9]), we examined more closely the response to reduced food intake in the C26 and PDA systems. In order to avoid the confounding effects of differing food intake patterns that are well documented as a problem of pair-feeding experiments ([@bib7]), we subjected weight-stable, pre-cachectic C26- and PDA-bearing mice, and the respective non-tumor-bearing littermate control mice, to 24 hr total food restriction (TFR) ([Figures S1](#mmc1){ref-type="supplementary-material"}H and S1I). We measured endocrine markers and metabolites in all experimental groups ([Figures 1](#fig1){ref-type="fig"}C--1E and [S2](#mmc1){ref-type="supplementary-material"}A--S2D). Cachectic and food-restricted pre-cachectic C26- and PDA-bearing mice had lower plasma glucose and ketone levels relative to food-restricted non-tumor-bearing controls ([Figures 1](#fig1){ref-type="fig"}C, 1D, and [S2](#mmc1){ref-type="supplementary-material"}C). Metabolic stress, as measured by plasma levels of corticosterone, occurred in all food-restricted and cachectic mice ([Figure 1](#fig1){ref-type="fig"}E), but the highest corticosterone levels were observed in the food-restricted pre-cachectic groups, presumably in response to low levels of ketones and glucose ([Figures 1](#fig1){ref-type="fig"}C--1E, [S2](#mmc1){ref-type="supplementary-material"}C, and S2D) ([@bib1]). Low levels of ketones and raised glucocorticoid levels during periods of continuous weight loss are not restricted to mouse models of cancer, for they were also present in patients with PDA and cachexia ([Figures 1](#fig1){ref-type="fig"}F, 1G, [S1](#mmc1){ref-type="supplementary-material"}J, and S1K).

Ketogenesis occurs in the liver and depends on the transcription factor PPARalpha, as demonstrated by the severely impaired ketogenesis in mice with a germline deletion of the *Ppara* gene ([@bib19]). Hepatic *Ppara* mRNA levels were significantly lower in pre-cachectic C26- and PDA-bearing mice than in non-tumor-bearing control mice. They were further decreased in both cachectic and food-restricted pre-cachectic C26- and PDA-bearing mice, but not in the food-restricted non-tumor-bearing control groups ([Figure 2](#fig2){ref-type="fig"}A). Hepatic mRNA levels for *Acadm* and *Hmgsc2*, target genes of PPARalpha ([@bib23]), were significantly decreased in all tumor-bearing mice that exhibited suppression of *Ppara* mRNA ([Figures 2](#fig2){ref-type="fig"}B and 2C). The products of these genes mediate the mitochondrial beta oxidation and conversion to ketones of the free fatty acids that have been released from adipose tissues during caloric deprivation. Their relatively diminished level of expression may therefore explain the low ketone levels that we observed in cachectic mice and food-restricted pre-cachectic mice. Impaired ketogenic potential in food-restricted pre-cachectic C26- and PDA-bearing mice was confirmed by the significantly reduced blood ketone levels following intraperitoneal (i.p.) administration of the ketogenic substrate, octanoate ([@bib26]), as compared to the ketone levels in the food-restricted non-tumor-bearing control groups ([Figure 2](#fig2){ref-type="fig"}D). Food-restricted PDA-bearing mice also exhibited reduced blood glucose in response to octanoate challenge relative to their control group ([Figure S2](#mmc1){ref-type="supplementary-material"}E). These experiments do not exclude an additional contribution to fasting hypoketonemia by the depletion of adipose tissues, which was particularly pronounced in the cachectic relative to the food-restricted pre-cachectic groups ([Figures S1](#mmc1){ref-type="supplementary-material"}D, S1F, and S1I), but they correspond directly to findings from models of PPARalpha deletion and hepatic PPARalpha dysfunction ([@bib5], [@bib19], [@bib36]). Taken together, these findings demonstrate that the ketogenic potential of the liver is impaired in pre-cachectic mice, most likely because of suppressed *Ppara* expression, and that this tumor-induced metabolic reprogramming exacerbates metabolic stress during subsequent periods of caloric deficiency.

IL-6 Is Necessary and Sufficient to Suppress Hepatic Ketogenesis in Pre-cachectic Mice {#sec2.2}
--------------------------------------------------------------------------------------

To investigate the mechanistic basis of tumor-induced suppression of hepatic *Ppara* and ketogenesis, we first performed a screen of tumor-associated cytokines and chemokines in the plasma of C26- and PDA-bearing mice. Given that the tumor-induced suppression of hepatic *Ppara* and ketogenesis was observed even in pre-cachectic C26- and PDA-bearing mice ([Figures 2](#fig2){ref-type="fig"}A--2D), we reasoned that the tumor-associated cytokine that accounted for these effects would be elevated in both pre-cachectic and cachectic mice from each model system. Of the cytokines that we screened, only IL-6 fulfilled this criterion ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A--S3C). Although TNFα was elevated in pre-cachectic and cachectic mice with PDA, plasma levels of this cytokine were unchanged in mice bearing C26 tumors. We also observed significantly elevated IL-6 levels in pre-cachectic and cachectic patients with PDA ([Figure 3](#fig3){ref-type="fig"}B). Importantly, this observation is consistent with the data from C26- and PDA-bearing mice outlined above ([Figure 3](#fig3){ref-type="fig"}A), as well as with previous reports of elevated IL-6 levels in patients with PDA and with other cachexia-associated cancers ([@bib38], [@bib8], [@bib28]).

To determine whether IL-6 contributed to the regulation of hepatic *Ppara* expression and ketogenesis, we infused recombinant IL-6 or PBS into non-tumor-bearing littermate mice for 72 hr, with the highest rate of infusion achieving plasma IL-6 levels comparable to those occurring in pre-cachectic and cachectic C26- and PDA-bearing mice ([Figure 3](#fig3){ref-type="fig"}C). During the final 24 hr, we subjected the mice to TFR. The recombinant IL-6 dose-dependently suppressed hepatic mRNA levels for *Ppara*, *Acadm*, and *Hmgcs2* and lowered fasting glucose and ketone levels while elevating fasting corticosterone levels ([Figures 3](#fig3){ref-type="fig"}D--3F). These changes were observed in the absence of IL-6-dependent alterations in body weight kinetics, body composition, and changes in pre-fasting plasma corticosterone levels ([Figures S3](#mmc1){ref-type="supplementary-material"}D--S3F).

We then determined whether the elevated IL-6 in tumor-bearing mice accounted for the suppression of hepatic *Ppara* and ketogenesis by administering neutralizing anti-IL-6 antibody to pre-cachectic mice with C26 tumors for 72 hr, during which TFR was imposed for the final 24 hr. Anti-IL-6 administration partially restored not only the hepatic mRNA levels of *Ppara*, *Acadm*, and *Hmgcs2*, but also the ketogenic response to the octanoate challenge ([Figures 4](#fig4){ref-type="fig"}A and 4B). These changes were also associated with an improved metabolic response to fasting, as reflected by the normalized plasma levels of glucose, ketones, and corticosterone ([Figures 4](#fig4){ref-type="fig"}C and 4D). Anti-IL-6 administration did not change body weight kinetics, body composition, tumor growth, serum markers of hepatocellular damage, or pre-fasting food intake ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4G).

The results from the above experiments clarify some important aspects underlying the suppression of hepatic ketogenesis and elevated corticosterone levels observed in our pre-cachectic model systems following food restriction. The reduced ketogenesis cannot be ascribed to reduced fat stores ([Figures S1](#mmc1){ref-type="supplementary-material"}D, S1F, and S1I) because both gain- and loss-of-function experiments involving IL-6 were performed with mice that were initially matched for fat stores, and there were no IL-6-dependent alterations of fat mass ([Figures S3](#mmc1){ref-type="supplementary-material"}E and [S4](#mmc1){ref-type="supplementary-material"}E). Likewise, although IL-6 has previously been reported as a direct activator of the hypothalamic-pituitary-adrenal axis ([@bib45]), this mechanism cannot account for the corticosterone elevations that were observed in the C26 and PDA model systems under food restriction ([Figure 1](#fig1){ref-type="fig"}E). Pre-cachectic C26- and PDA-bearing mice exhibited normal corticosterone levels despite raised IL-6 levels ([Figures 1](#fig1){ref-type="fig"}E and [3](#fig3){ref-type="fig"}A), and IL-6 infusion did not elevate corticosterone in the absence of food restriction ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Taken together, these data support the conclusion that tumor-induced IL-6 is both necessary and sufficient to suppress the potential of the liver for ketogenesis. This metabolic switch, however, does not affect glucocorticoid levels until the imposition of caloric deficiency, where hepatic ketogenesis is required to support the energy demands of the brain ([@bib4]). The circumstance of caloric deficiency leads to the metabolic stress that induces the marked glucocorticoid response ([Figures 1](#fig1){ref-type="fig"}E, [3](#fig3){ref-type="fig"}F, and [4](#fig4){ref-type="fig"}D).

Tumor-Induced Metabolic Stress Is Coupled with Suppressed Intratumoral Immunity {#sec2.3}
-------------------------------------------------------------------------------

We addressed the possibility that the cachexia-associated alterations of host metabolism ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [S1, and S2](#mmc1){ref-type="supplementary-material"}) might affect tumor biology by comparing the transcriptomes of C26 tumors taken from pre-cachectic and cachectic mice. Unsupervised analysis of the RNA sequencing (RNA-seq) data distinguished the tumors taken from pre-cachectic and cachectic C26-bearing mice ([Figure S5](#mmc1){ref-type="supplementary-material"}A), and between-group comparisons yielded 2,973 differentially expressed genes at a false discovery rate (FDR) \< 0.05 ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Downregulation in the tumors from cachectic mice was the dominant phenomenon, and of the 30 most downregulated pathways identified by a gene set enrichment analysis (GSEA) (FDR ≤ 0.001 for each of the 30 pathways), 29 were related to either innate or adaptive immunity ([Figure 5](#fig5){ref-type="fig"}A). No significantly upregulated pathways (FDR \< 0.25) were identified by the analysis. A MetaCore enrichment analysis yielded similar results ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5E). A review of the list of differentially expressed genes indicated that the dominant pathway alterations resulted from reduction of multiple immune cell types, including the CD4+, CD8+, and natural killer (NK) lymphocyte populations, in C26 tumors from cachectic mice ([Table S1](#mmc1){ref-type="supplementary-material"}). Also reduced were transcripts for molecules involved in lymphocyte chemotaxis (*Cxcl9--11*), and CD4+ Th1 and CD8+ T cell effector function (*Ifng*, *Gzmb*, and *Prf1*). The myeloid compartment was also affected in these C26 tumors from cachectic mice, as demonstrated by a decrease in the levels of transcripts for *Itgam*, *Itgax*, and *Cd74* (CD11b, CD11c, and MHC II, respectively) ([Table S1](#mmc1){ref-type="supplementary-material"}). The cachexia-associated depletion of intratumoral CD3+ T cells was confirmed by immunohistochemistry ([Figure S5](#mmc1){ref-type="supplementary-material"}D). Flow cytometric analysis using markers for lymphoid cells was performed on C26 tumors from independent cohorts of pre-cachectic and cachectic mice ([Figures 5](#fig5){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}F). In addition to the cachexia-associated loss of CD3+ T cells, this analysis demonstrated the depletion of CD8+ T cells, CD4+Foxp3− T cells, and NK cells. A trend toward reduced numbers of CD4+Foxp3+ T cells was also observed ([Figure 5](#fig5){ref-type="fig"}B).

We determined whether the immunological phenotype of C26 tumors taken from cachectic mice could be induced by food restriction of pre-cachectic C26-bearing mice. Since adaptive immune control of tumor growth depends on the intratumoral accumulation and function of T cells ([@bib27], [@bib44]), we measured the expression of a panel of eight genes relating to these immune phenomena that were suppressed in tumors from cachectic mice: the CXCR3-dependent chemotaxis of T cells (*Cxcl9*, *Cxcl10*, and *Cxcl11*), the presence of T cells (*Cd8a* and *Cd3e*), and their effector functions (*Gzmb*, *Prf1*, and *Ifng*). Food-restricted pre-cachectic C26-bearing mice exhibited reductions in the expression of this immune gene panel that were similar to those that were observed in cachectic C26-bearing mice ([Figures 5](#fig5){ref-type="fig"}C and 5D). Forty percent partial food restriction, relative to baseline food intake, of pre-cachectic C26-bearing mice also induced metabolic stress, as reported by elevated plasma corticosterone levels; suppressed the expression of the selected immunological genes; and reduced the numbers of intratumoral CD3+ T cells relative to ad libitum-fed pre-cachectic C26-bearing mice ([Figures 5](#fig5){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}A--S6E). Taken together, these findings demonstrate that the metabolic stress of caloric deficiency, whether spontaneous or experimentally induced, in C26-bearing mice suppresses intratumoral T cell immunity.

Glucocorticoids, Induced by Metabolic Stress, Suppress Intratumoral Immunity {#sec2.4}
----------------------------------------------------------------------------

The cachexia-associated phenotypes of reprogrammed hepatic metabolism with metabolic stress ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [4](#fig4){ref-type="fig"}) and suppressed intratumoral immunity ([Figures 5](#fig5){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}) were both induced by food restriction of pre-cachectic mice. We considered the possibility that the two responses were linked by the marked stress-induced elevations in glucocorticoids ([Figures 1](#fig1){ref-type="fig"}E, [3](#fig3){ref-type="fig"}F, [4](#fig4){ref-type="fig"}D, and [S2](#mmc1){ref-type="supplementary-material"}D) because glucocorticoids are clinically used as potent pharmacological immune suppressants. We first assessed whether the immune gene panel of the C26 tumor in freely feeding pre-cachectic mice was sensitive to physiological, diurnal variation in plasma corticosterone levels. Expression of six of the eight genes in the panel was significantly lower in C26 tumors taken at 1700 hr, as compared to their expression in tumors taken at 0900 hr, which correlated with the peak and nadir, respectively, of the plasma corticosterone levels ([Figures 6](#fig6){ref-type="fig"}A and 6B). The possibility that these immune changes reflected a marked sensitivity of the C26 tumor microenvironment to corticosterone was examined by implanting subcutaneous pellets continuously releasing corticosterone at 0.01 mg/hr for 7 days in C26-bearing mice, which resulted in plasma corticosterone levels at 0900 and 1700 hr that were equivalent to the peak diurnal level ([Figure 6](#fig6){ref-type="fig"}B). This modest alteration in physiological corticosterone levels was sufficient to induce the phenotype of cachexia-associated intratumoral immune suppression when assessed transcriptionally and histologically ([Figures 6](#fig6){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}F). Increasing the corticosterone pellet release to 0.02 mg/hr dose dependently led to higher plasma corticosterone levels (354.5 ± 17.7 ng/mL SEM) but did not further suppress the expression of the immune gene panel or the intratumoral CD3+ T cell percentages ([Figures 6](#fig6){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}F). Flow cytometric analysis of tumors from an independent cohort of C26-bearing mice that were implanted with the 0.01 mg/hr corticosterone pellets confirmed depletion of CD3+ T cells, CD8+ T cells, CD4+Foxp3− T cells, CD4+Foxp3+ T cells, and NK cells ([Figure S6](#mmc1){ref-type="supplementary-material"}G). This marked sensitivity of the immune C26 tumor microenvironment to corticosterone was also reflected by the correlation between anti-IL-6-induced decreased plasma levels of the hormone and increased mRNA levels of *Cxcl9*, *Cxcl10*, and *Cxcl11* in food-restricted pre-cachectic C26-bearing mice ([Figure S6](#mmc1){ref-type="supplementary-material"}H).

These experiments demonstrating the sensitivity of the immune microenvironment of the C26 tumors to changes in corticosterone levels did not exclude the possibility that other consequences of caloric deficiency and metabolic stress in tumor-bearing mice might contribute to immune suppression. To evaluate this possibility, pre-cachectic C26-bearing mice that were subjected to 24 hr TFR were administered the glucocorticoid synthesis inhibitor, aminoglutethimide, or vehicle control. Relative to freely feeding controls, the food-restricted, vehicle-treated group exhibited elevated plasma corticosterone levels, reduced expression of the intratumoral immune panel of genes, and fewer intratumoral T cells and NK cells ([Figures 6](#fig6){ref-type="fig"}D--6F and [S7](#mmc1){ref-type="supplementary-material"}A). Trends toward fewer CD4+Foxp3− T cells and CD4+Foxp3+ T cells were also observed ([Figure 6](#fig6){ref-type="fig"}F). Aminoglutethimide inhibited the fasting-induced corticosterone production ([Figure 6](#fig6){ref-type="fig"}D) and all changes relating to intratumoral immunity ([Figures 6](#fig6){ref-type="fig"}E, 6F, and [S7](#mmc1){ref-type="supplementary-material"}A), despite a further reduction in blood glucose levels ([Figure S7](#mmc1){ref-type="supplementary-material"}B). These findings indicate that elevated corticosterone is the primary metabolic mediator of intratumoral immune suppression during caloric deficiency in pre-cachectic tumor-bearing mice.

Stress-Induced Glucocorticoids Cause Failure of Cancer Immunotherapy {#sec2.5}
--------------------------------------------------------------------

Human PDA has not responded to therapy with antagonists of T cell checkpoints ([@bib3], [@bib35]), and the mouse model of this disease is also resistant to antibodies specific for PD-1, PD-L1, and CTLA-4 ([@bib12], [@bib48]). Consistent with this lack of response of PDA to stimulators of T cell function, and consistent with the low numbers of intratumoral T cells predicting failure of immunotherapy ([@bib44]), are the markedly lower levels of intratumoral transcripts relating to T cell immunity in pre-cachectic PDA-bearing mice as compared to their levels in pre-cachectic C26-bearing mice ([Figure 7](#fig7){ref-type="fig"}A). We examined whether this contrasting immune microenvironment also exhibited sensitivity to metabolic stress. Subjecting pre-cachectic PDA-bearing mice to 24 hr of TFR reduced expression of *Cxcl9* and *Gzmb*, with trends toward reduced expression for *Cxcl10* and *Ifng* ([Figure 7](#fig7){ref-type="fig"}A). Continuously elevating corticosterone levels in PDA-bearing mice for 6 days using a 0.02 mg/hr corticosterone infusion also suppressed the expression of *Cxcl9*, *Cxcl10*, and *Ifng*, with trends toward reduced expression of *Gzmb* and *Prf1* ([Figures 7](#fig7){ref-type="fig"}B and 7C).

The potential clinical relevance of the sensitivity of the immune microenvironment of mouse PDA to glucocorticoids was assessed by examining the effect of elevated corticosterone levels on immunotherapy in this model. Pre-clinical experiments have demonstrated T cell-dependent control of PDA growth in mice receiving the selective CXCR4 antagonist, AMD3100, in combination with anti-PD-L1 ([@bib12]). We treated freely feeding, weight-stable pre-cachectic PDA-bearing mice for 6 days with a continuous infusion of AMD3100 or PBS, in combination with anti-PD-L1 or isotype control antibody, in the context of subcutaneous pellets releasing corticosterone at a rate of 0.02 mg/hr or placebo control pellets. In mice with control pellets, this immunotherapy arrested PDA growth ([Figure 7](#fig7){ref-type="fig"}D). In contrast, in mice with corticosterone-releasing pellets that resulted in elevated plasma levels of the hormone, which were lower than those of cachectic or food-restricted pre-cachectic PDA-bearing mice ([Figure 7](#fig7){ref-type="fig"}C) and comparable to the fold elevations observed in human cachexia ([Figure 1](#fig1){ref-type="fig"}G), this immunotherapy failed to control PDA growth ([Figure 7](#fig7){ref-type="fig"}E). AMD3100 plasma levels were comparable in the placebo and corticosterone-infused groups (1,020 ± 63.0 ng/mL SEM versus 1,310 ± 161 ng/mL SEM, respectively). Through infusion of glucocorticoids at doses that are relevant both physiologically and clinically, we have thus demonstrated a direct link between the tumor-induced alteration in the metabolic response to caloric deprivation and failure of PDA tumors to respond to immunotherapy.

Discussion {#sec3}
==========

We have demonstrated in two mouse models of cancer-induced cachexia that in pre-cachectic mice, even before the onset of the weight-losing phase of the syndrome, tumor-induced IL-6 has altered the capacity of the liver to respond to caloric deprivation. Through a suppression of ketogenesis that is attributable to suppression of its transcriptional master regulator, PPARalpha, this tumor-induced reprogramming of hepatic metabolism has removed an important component of the host's capacity to make available endogenous sources of energy that compensate for decreased caloric intake. This compounding of the energy deficit magnifies the host stress response and leads to glucocorticoid levels that are more than sufficient to suppress tumor immunity, especially when considering the sensitivity of the immune tumor microenvironment even to diurnal variations of the hormone. This apparently paradoxical metabolic response to caloric deficiency may subvert therapeutic interventions designed to correct other causes of the failure of tumor immune surveillance, such as poor immunogenicity and local immune privilege ([@bib16], [@bib22], [@bib46]). The translational relevance of our study is emphasized by validation of all key aspects of the metabolic and immunological phenotypes, and performance of the immune therapy experiment, in the KPC autochthonous PDA model, which recapitulates human PDA and is the accepted model for pre-clinical studies of this cancer ([@bib25], [@bib32]). In addition, this study demonstrates, in accordance with our murine data, that some patients with pancreatic cancer exhibit raised IL-6 levels when they are pre-cachectic, and that they may exhibit the triad of raised IL-6 levels, reduced ketone levels, and raised glucocorticoid levels when they are cachectic.

The finding that tumor-induced IL-6 suppresses PPARalpha-regulated ketogenesis was confirmed mechanistically, in vivo, through both gain- and loss-of-function studies ([Figures 3](#fig3){ref-type="fig"}C--3F, [4](#fig4){ref-type="fig"}A--4D, [S3](#mmc1){ref-type="supplementary-material"}D--S3F, and [S4](#mmc1){ref-type="supplementary-material"}A--S4G). This ketogenic deficit was shown to be independent of decreased fat mass ([Figures S3](#mmc1){ref-type="supplementary-material"}E and [S4](#mmc1){ref-type="supplementary-material"}E) and, importantly, to be induced by infusing IL-6 in the absence of a tumor ([Figures 3](#fig3){ref-type="fig"}C--3F). The mechanism whereby IL-6 impinged upon the expression of PPARalpha in the liver is not addressed by our study, although as PPARalpha regulates its own transcription ([@bib23]), suppressed expression may relate to deprivation of the physiological ligand for PPARalpha ([@bib5]) or repression of the peroxisome proliferator response element (PPRE) ([@bib36]). The finding that tumor-induced IL-6 was both necessary and sufficient to suppress hepatic ketogenesis, taken together with the fact that consistent elevations of other cytokines were not detected in our model systems, indicates that the effects on hepatic metabolism of other cytokines are less relevant in this metabolic context. Finally, we have not addressed the possibility that the fatty acids that are liberated from adipose tissue and not readily metabolized by reprogrammed livers may be a source of macronutrients to be used by cancer cells for growth ([@bib18]). Nevertheless, the observation of tumor-induced IL-6 reprogramming hepatic ketogenesis, when taken together with the recent report of lung cancer rewiring hepatic circadian homeostasis involving insulin, glucose, and lipid metabolism ([@bib24]), suggests that the liver may be a specific target of tumor-induced effects on the host, presumably for the benefit of the tumor and the detriment of the host.

The results relating to hepatic metabolism alone may have multiple clinical implications. Hepatic ketone body production is essential in order to spare glucose and support brain function during periods of caloric insufficiency ([@bib4]). The responses of blood ketones and glucose in fasted pre-cachectic mice to the exogenous fatty acid substrate, octanoate, were directionally opposed relative to the responses of non-tumor-bearing controls ([Figures 2](#fig2){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}E), indicating severely compromised nutrient processing, and perhaps explaining why conventional nutritional support has so far been ineffective in cachectic cancer patients ([@bib41]). Such aberrant liver metabolism may not be limited to the context of cancer: the hepatic effect of IL-6 in tumor-free mice is dose dependent across the range observed in tumor-bearing mice ([Figures 3](#fig3){ref-type="fig"}A, 3C, and 3D), implicating the process in a wide range of IL-6-associated diseases where weight loss is observed, such as sepsis, HIV, tuberculosis, chronic obstructive pulmonary disease, cardiac failure, and rheumatoid arthritis. In terms of therapeutic reversibility, our body composition data following acute IL-6 neutralization are consistent with existing clinical data regarding the failure of anti-IL-6 to improve wasting parameters in cachectic patients without concomitant correction of caloric deficiencies ([@bib10]). When taken with the more subtle effects on metabolism, and in particular the rescue of the octanoate response ([Figure 4](#fig4){ref-type="fig"}B), these data suggest that successful reversal of cachexia may require co-administration of anti-IL-6 with nutritional support.

In the context of caloric deficiency, where ketogenesis is normally activated to provide energy substrates that are essential to support brain function ([@bib4]), IL-6-induced metabolic reprogramming leads directly to the phenotype of glucocorticoid-induced immune suppression within the tumor microenvironment. Initially observed in an unbiased comparison of the transcriptomes of the C26 tumors in cachectic and pre-cachectic mice, and then shown to be a consequence of the compensatory glucocorticoid response to caloric deficiency, this immunological phenotype exhibited an internally consistent cluster of findings: decreased levels of *Cxcl9*, *Cxcl10*, and *Cxcl11* mRNA in association with fewer lymphocytes and diminished mRNA levels of the lymphocyte effector genes, *Ifng*, *Gzmb*, and *Prf1* ([Figures 5](#fig5){ref-type="fig"}A--5E, [6](#fig6){ref-type="fig"}A--6F, [S6](#mmc1){ref-type="supplementary-material"}A--S6G, and [S7](#mmc1){ref-type="supplementary-material"}A). We focused our attention on these markers because CXCR3 signaling is required for T cell infiltration into tumor sites ([@bib27]), and the relative intensity of intratumoral T cell infiltration predicts both cancer survival and the response to anti-cancer immunotherapy in humans ([@bib13], [@bib34], [@bib44]). The transcriptional findings were recapitulated in the PDA model system ([Figures 7](#fig7){ref-type="fig"}A and 7B). Glucocorticoid sensitivity was thus observed in tumor immune microenvironments with high and low levels of immunological activity. This is translationally relevant because tumors from patients with cancer exhibit a wide spectrum of immunological activity ([@bib34]). Among the many potential mechanisms mediating the immunosuppressive effects of glucocorticoids, the diminished expression of *Cxcl9--11* suggests that the most relevant cellular target of the elevated glucocorticoids may be the intratumoral myelomonocytic cell. Deletion of NR3C1, the glucocorticoid receptor, in these cells has been shown to abolish glucocorticoid-dependent suppression of the expression of *Cxcl10* and other chemotactic factors in a contact hypersensitivity reaction ([@bib43]).

A potential biological role for this metabolic pathway may be to suppress immunological damage to inflamed, non-infected tissues since many inflammatory conditions are associated with anorexia, high IL-6 levels, and elevated serum glucocorticoids. In the context of inflammation associated with cancer, however, this metabolic pathway subverts the host's capacity to mediate immune control of the cancer. Providing exogenous corticosterone in freely feeding pre-cachectic PDA-bearing mice isolated the effects of this hormone from other alterations associated with cachexia, thereby permitting an evaluation of its effects on anti-tumor immunotherapy. Corticosterone levels that were below the range observed in cachectic or food-restricted pre-cachectic mice were sufficient to abolish the anti-tumor effect of dual CXCR4 and PD-L1 antagonism in mice bearing autochthonous PDA ([Figures 7](#fig7){ref-type="fig"}C--7E). Cachexia is a frequent occurrence in human pancreatic cancer ([@bib2]), associated with fold elevations of glucocorticoids that are comparable to those achieved during the corticosterone infusions ([Figures 1](#fig1){ref-type="fig"}G, [6](#fig6){ref-type="fig"}B, and [7](#fig7){ref-type="fig"}C), and known to be reversible upon tumor shrinkage or removal ([@bib11], [@bib39]). These observations, together with the recently initiated clinical trials involving CXCR4 antagonism with or without co-targeting of the PD-1:PD-L1 axis in PDA ([NCT02179970](ctgov:NCT02179970){#intref0010}; [NCT02472977](ctgov:NCT02472977){#intref0015}), attest to the clinical relevance of our findings.

In conclusion, we have unveiled a new aspect of how metabolism in tumor-bearing hosts is reprogrammed in the pre-cachectic state. Such metabolic dysregulation can ultimately lead to failure of host immunity to control cancer in the context of anti-cancer immunotherapy. Prior resolution of such deranged metabolism through a combination of IL-6 neutralization and hyperalimentation may be necessary in order to maximize the proportion of patients that respond to these therapies. Rescue of immunotherapeutic efficacy may also be achieved in a more direct manner, through inhibition of glucocorticoid synthesis. In turn, glucocorticoid levels themselves may be of use as biomarkers in the context of immunotherapy. Future clinical studies of both cachexia-modulating interventions and anti-cancer immune therapies may need to take these findings into consideration in order to optimize the selection of therapeutic combinations and the discovery of biomarkers.

Experimental Procedures {#sec4}
=======================

Full experimental procedures are provided in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Animal Experiments {#sec4.1}
------------------

All experiments were performed in accordance with national and institutional guidelines and approved by the UK Home Office, the animal ethics committee of Cancer Research UK Cambridge Institute, and the University of Cambridge. The C26 model experiments were performed on wild-type male BALB/c mice, which were kept on a 24 hr 12:12 light-dark cycle and inoculated with 2^∗^10^6^ viable cells subcutaneously (s.c.). Mice were termed pre-cachectic from 18 days post-inoculation. Cachexia was defined as \>5% loss from peak body weight.

PDA was detected via ultrasound in KPC mice. Mice with maximum average PDA tumor diameters \>4 mm were defined as pre-cachectic.

i.p. injections were administered as follows: anti-IL-6 (MP5.20F3) and isotype IgG1 (HRPN) at 48 hr prior to and at the point of TFR (1.25 mg per injection); sodium octanoate at 24 hr post-TFR (6 mL/kg of 200 mM); aminoglutethimide at 0, 8, and 16 hr post-TFR (37.5 mg/kg per injection); and anti-PD-L1 on days 0, 2, and 4 (200 μg per injection). Corticosterone or placebo pellets and osmotic minipumps loaded with AMD3100, recombinant IL-6, or PBS were implanted s.c.

Murine Blood and Plasma Measurements {#sec4.2}
------------------------------------

Blood samples were kept on ice. Plasma and tissues were snap frozen in liquid nitrogen and stored at −80°C. Tail bleeds were analyzed for glucose and ketone concentrations using gluco- and ketometers. Corticosterone was quantified using ELISA. Terminal cardiac bleed plasma glucose and ketone levels were assessed using the Siemens Dimension RxL analyzer and the Stanbio Beta Hydroxybutyrate Liquicolor kit, respectively. Insulin, leptin, and cytokines were measured using MesoScale Discovery kits. IL-6 levels were measured using ELISA.

AMD3100 was extracted from plasma samples pre-spiked with internal standard (D4-labeled AMD3100) and EDTA by protein precipitation with methanol. Quantitation was by liquid chromatography-tandem mass spectrometry (LC-MS/MS) over a calibration range of 50--5,000 ng/mL.

qRT-PCR {#sec4.3}
-------

mRNA was extracted from snap-frozen tissues using TRIzol Reagent. mRNA templates were diluted to 2 ng/μL (muscle and liver) or 30 ng/μL (tumor) and analyzed by quantitative real-time PCR. mRNA levels were normalized to either Rn18s (liver and tumor) or Tbp (quadriceps) using the ddCt method.

RNA-Seq {#sec4.4}
-------

RNA extracted from frozen tissues via TRIzol was run through QIAGEN RNeasy columns following the "RNA cleanup" protocol. Integrity was confirmed using RIN values with a cut-off of 8, and libraries were prepared using the Illumina TruSeq mRNA Stranded Sample prep kit (96 index high throughput) using twelve rounds of PCR. Libraries were quantity and quality checked and normalized. The final pooled library was run on a MiSeq to assess final sequencing quality before HiSeq 2500 V4 single-end 50 bp sequencing. We aimed to generate 10--20 M single-end 50 bp reads per sample.

For the analysis, single-end 50 bp reads were aligned to the mouse genome version GRCm38.74 using TopHat v2.0.4. Read counts were obtained using HTSeq-count v0.5.3p9. Read counts were normalized and tested for differential gene expression using the Bioconductor package DESeq v1.10.1. Multiple testing correction was applied using the Benjamini-Hochberg method. The data can be accessed at [http://dx.doi.org/10.17863/CAM.4930](10.17863/CAM.4930){#intref0020}.

GSEA was performed by ranking all genes tested in RNA-seq using --log~10~ (p values) derived from differential expression analyses and testing against MSigDB Canonical Pathways (C2:CP). MetaCore enrichment analyses gated on the significantly (FDR \< 0.05) up- and downregulated genes were also performed using MetaCore's pathway maps database.

Immunohistochemistry {#sec4.5}
--------------------

Tissues were fixed in 10% neutral buffered formaldehyde. Immunohistochemistry was performed for CD3 using a Leica Bond III immunostainer. Deparaffinization and rehydration were conducted before antigen retrieval was performed using Tris EDTA (pH 9) (ER2) for 20 min at 100°C, incubation in a rabbit polyclonal anti-CD3 antibody (A0452) for 15 min, HRP-linked anti-rabbit polymer for 8 min, diaminobenzidine for 10 min, and DAB Enhancer (Leica) for 10 min. Counterstaining was with hematoxylin for 2 min. The slides were scanned at 20× on a Leica AT2 and subsequently analyzed in a blinded manner using the Cytonuclear v1.4 algorithm on the HALO platform.

Flow Cytometry {#sec4.6}
--------------

C26 tumors were mechanically and enzymatically homogenized using buffer containing RPMI with 1 mg/mL collagenase (Sigma C0130) and 0.1 mg/mL DNase (Sigma D4527). Cells were stained for flow cytometry according to reagent manufacturers' protocols. Viability was determined using eBioscience e780 fixable viability dye at a 1/1,000 dilution. All antibodies are listed in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. CD49b positivity was determined using a fluorescence-minus-one control. Anti-CD16/32 (unconjugated; 2.4G2; 5 μg/mL; BD) was used for Fc blocking prior to antibody staining. The eBioscience Foxp3/Transcription Factor Fixation/Permeabilization Concentrate and Diluent was used prior to Foxp3 staining. Sample analysis was performed using an LSR II cytometer. At least 200,000 events per tumor sample were collected. Data were subsequently analyzed using FlowJo.

Human Studies {#sec4.7}
-------------

The study and the sample acquisition were performed in concordance with local and national guidelines. Patients at least 18 years old with histologically confirmed pancreatic adenocarcinoma were recruited in the outpatient department of the Cambridge University Hospital NHS Foundation Trust as part of the CAMPAN study. All participants provided written informed consent. All samples were taken between 1300 and 1500 hr. Patients were designated cachectic if they met the international consensus definition for cachexia, i.e., if they exhibited weight loss of \>5% over past 6 months (in the absence of simple starvation) or BMI \< 20 and ongoing weight loss of more than 2% ([@bib9]). Serum cortisol levels were assessed using the Cortisol Parameter Assay kit from R&D Systems. Serum IL-6 levels were assessed using ELISA. Ketone levels from plasma were assessed using Freestyle Optium Neo ketometers (Abbott Laboratories).

Statistical Analysis {#sec4.8}
--------------------

Statistical analyses, unless otherwise indicated, were performed using GraphPad Prism 6.
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![The Metabolic Response to Spontaneous or Imposed Food Restriction of Pre-cachectic Mice Bearing Transplantable C26 Tumors or Autochthonous PDA, and Translational Correlates in Patients with PDA\
Weight-stable mice with established C26 or PDA tumors that were yet to develop cachexia were termed pre-cachectic (C26/PreCx and PDA/PreCx, respectively). C26- and PDA-bearing mice were termed cachectic (C26/Cx and PDA/Cx, respectively) following \>5% body weight loss from their peak weight.\
(A and B) Body weight (A) and cumulative food intake (B) were monitored in C26/PreCx, C26/Cx, PDA/PreCx, and PDA/Cx mice, and measurements were aligned to the time of sacrifice.\
(C--E) Terminal bleed plasma levels of (C) glucose and (D) ketones and tail bleed plasma levels of (E) corticosterone were assessed in littermates (LM), C26/PreCx and C26/Cx mice, and LM and C26/PreCx mice that had been subjected to 24 hr TFR (LM + TFR and C26/PreCx + TFR, respectively). Parallel assessments were performed in PDA-bearing mice, with LSL-Trp53^R172H/+^; Pdx-1-Cre/+ (PC) mice as the non-tumor-bearing controls.\
(F) Longitudinal pre-sampling weights for pre-cachectic and cachectic patients with pancreatic cancer are displayed.\
(G) Midday serum cortisol levels for both groups of patients are shown. The comparisons of data for LM, C26/PreCx, and C26/Cx mice, and for PC, PDA/PreCx, and PDA/Cx mice, were performed using one-way ANOVA with Tukey's correction for post hoc testing. The LM + TFR versus C26/PreCx + TFR, PC + TFR versus PDA/PreCx + TFR, and pre-cachectic versus cachectic patient comparisons were each performed separately using two-tailed t tests with Welch's correction.\
^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. Data are presented as mean ± SEM.](gr1){#fig1}

![Reprogrammed Hepatic Response to Caloric Deprivation in Pre-cachectic and Cachectic Mice\
(A--C) mRNA expression levels of (A) *Ppara*, (B) *Acadm*, and (C) *Hmgcs2* genes involved in mitochondrial beta-oxidation and ketogenesis were measured via qRT-PCR in livers taken from LM, C26/PreCx, C26/Cx, LM + TFR, C26/PreCx + TFR, PC, PDA/PreCx, PDA/Cx, PC + TFR, and PDA/PreCx + TFR mice. All measurements were normalized to the respective freely feeding non-tumor-bearing control groups.\
(D) The ketogenic reserve was assessed in LM + TFR, C26/PreCx + TFR, PC + TFR, and PDA/PreCx + TFR mice in vivo by administration of sodium octanoate 24 hr post-TFR. Blood ketone concentrations were measured for up to 180 min post-substrate administration (n = 7--12 per group). The comparisons between LM, C26/PreCx, and C26/Cx mice, and between PC, PDA/PreCx, and PDA/Cx mice, were performed using one-way ANOVA with Tukey's correction for post hoc testing. Comparisons between LM + TFR and C26/PreCx + TFR mice, and between PC + TFR and PDA/PreCx + TFR mice, were performed using two-tailed t tests with Welch's correction.\
^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. Data are presented as mean ± SEM.](gr2){#fig2}

![Reprogramming of the Hepatic Response to Caloric Deficiency by IL-6\
(A) Plasma levels of IL-6 were measured in LM, C26/PreCx, C26/Cx, LM + TFR, C26/PreCx + TFR, PC, PDA/PreCx, and PDA/Cx mice.\
(B) IL-6 serum levels in pre-cachectic and cachectic patients with PDA, as well as levels of historical control volunteers (as reported by the assay manufacturer), are displayed.\
(C and D) Escalating doses of IL-6 were infused into non-tumor-bearing LM mice for 72 hr, with the final 24 hr under TFR. (C) IL-6 plasma levels and (D) hepatic mRNA levels for *Ppara*, *Acadm*, and *Hmgcs2* were assessed, the latter by qRT-PCR.\
(E and F) LM mice were administered 0.3 μg/hr IL-6 for 72 hr, with the final 24 hr under the condition of TFR. Tail vein bleeds were assessed for (E) glucose and ketone levels 18--24 hr post-TFR (n = 8 per group) and for (F) corticosterone levels 18 hr post-TFR.\
The measurements from (A) LM, C26/PreCx, and C26/Cx mice; (A) PC, PDA/PreCx, and PDA/Cx mice; as well as (B) control, pre-cachectic, and cachectic patients were compared using one-way ANOVA with Tukey's correction for post hoc comparisons. Comparisons of data at each time point in (E), of data in (F), and the comparison of LM +TFR versus C26/PreCx + TFR in (A) were performed using two-tailed t tests with Welch's correction. The dotted line in (B) and (C) represents the assay detection limit. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Data are presented as mean ± SEM.](gr3){#fig3}

![Neutralizing IL-6 Reverses Hepatic Reprogramming in C26-Bearing Mice\
(A) C26/PreCx mice were administered isotype control or neutralizing anti-IL-6 antibodies 48 hr prior to and at the initiation of TFR. Hepatic mRNA levels for *Ppara* and its target genes were measured by qRT-PCR 24 hr post-TFR.\
(B--D) Ketogenic response to octanoate 24 hr post-TFR (n = 7 per group) (B), glucose and ketone levels from tail bleeds 18--30 hr post-TFR (n = 10 per group) (C), and terminal bleed plasma corticosterone levels 24 hr post-TFR (D) were assessed.\
Data comparisons in (A) and (D) as well as comparisons at each time point in (C) were performed using two-tailed t tests with Welch's correction. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Within-group comparisons of (C) glucose data were performed relative to the 18 hr time point using ratio paired t tests (\#). For the (B) octanoate challenge, mice from the two groups were stratified by body weight prior to enrollment and the percent changes in blood ketones were compared by ratio paired t tests at each time point. Data are presented as mean ± SEM.](gr4){#fig4}

![Suppression of Intratumoral Immunity in Cachexia and Caloric Deficiency\
(A) RNA-seq data from whole-tumor lysates from C26/PreCx and C26/Cx mice were subjected to GSEA. The 30 most significantly downregulated gene sets in tumors from C26/Cx mice are presented. There were no significantly upregulated gene sets in tumors from C26/Cx mice at FDR \< 0.25.\
(B) The CD3+, CD8+, CD4+Foxp3−, CD4+Foxp3+, and NK cell populations of tumors from C26/PreCx and C26/Cx mice were enumerated using flow cytometry.\
(C--E) Levels of intratumoral transcripts of genes relevant to T cell-mediated immunity were determined via qRT-PCR of tumors taken from (C) C26/PreCx mice, C26/Cx mice, (D) C26/PreCx + TFR mice, and (E) C26/PreCx mice subjected to 3 days of 40% partial food restriction (C26/PreCx + 40% PFR) (n = 6--12 per group).\
The indicated data comparisons in (B)--(E) were performed using two-tailed t tests with Welch's correction. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Data are presented as mean ± SEM.](gr5){#fig5}

![Glucocorticoids Connect Reprogrammed Hepatic Metabolism to Suppressed Intratumoral Immunity\
(A) mRNA levels for immunological genes were measured via qRT-PCR in tumors taken from C26/PreCx mice at 0900 and 1700 hr (n = 12 per group).\
(B) C26-bearing mice were implanted with subcutaneous pellets releasing 0.01 mg/hr corticosterone, or with placebo pellets, and plasma corticosterone levels were measured at 0900 and 1700 hr on day 7 of the infusion via tail vein bleeds.\
(C) C26-bearing mice were implanted with placebo pellets, or pellets eluting either 0.01 mg/hr or 0.02 mg/hr corticosterone. Intratumoral mRNA levels of immunological genes were measured via qRT-PCR (n = 4--5 per group).\
(D--F) C26/PreCx mice were subjected to TFR and administered the glucocorticoid synthesis inhibitor, aminoglutethimide, or vehicle control. Tail bleed corticosterone levels (D), intratumoral mRNA levels of immunological genes as measured via qRT-PCR (n = 8--13 per group) (E), and flow cytometric analyses of lymphoid subpopulations (F) are displayed. The C26/PreCx 0900 hr versus C26/PreCx 1700 hr, C26/PreCx versus C26/PreCx + TFR + vehicle, and C26/PreCx + TFR + vehicle versus C26/PreCx + TFR + aminoglutethimide comparisons were all performed using two-tailed t tests with Welch's correction.\
Data in (B) were analyzed using two-way ANOVA with Tukey's correction for post hoc comparisons. Comparisons in (C) were performed using one-way ANOVA with Fisher's LSD (least significant difference) test for post hoc comparisons. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. Data are presented as mean ± SEM. Veh, vehicle; AG, aminoglutethimide.](gr6){#fig6}

![Glucocorticoids Suppress Intratumoral Immunity and Cause Failure of Cancer Immunotherapy in Autochthonous Mouse PDA\
(A and B) Pre-cachectic PDA-bearing mice were subjected to (A) TFR (n = 8--9 per group) or (B) 6 day infusions with subcutaneous pellets releasing 0.02 mg/hr corticosterone (n = 4--5 per group). Intratumoral mRNA levels for immunological genes were measured via qRT-PCR. The mRNA levels in the tumors from the C26/PreCx mice from [Figure 5](#fig5){ref-type="fig"}D are normalized to the levels from the PDA/PreCx group.\
(C) Tail bleed corticosterone levels from the corticosterone pellet-infused PDA/PreCx mice are displayed.\
(D and E) PDA mice were administered AMD3100 + anti-PD-L1, or PBS + isotype control antibody, and implanted with (D) placebo pellets or (E) pellets releasing 0.02 mg/hr corticosterone. Tumor volumes were assessed by ultrasound over a 6 day treatment period.\
The indicated statistical comparisons in (A)--(C), and comparisons at each time point in (D) and (E), were performed using two-tailed t tests with Welch's correction. Data in (A) and (B) were logarithmically transformed prior to statistical analysis. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. Data are presented as mean ± SEM.](gr7){#fig7}
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